Synthesis and structure–activity relationships of pyrazole-based inhibitors of meprin α and β

References

• Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov. 2010;9(9):690–701.
   PubMed Web of Science ®Google Scholar
• Gomis-Rüth FX, Trillo-Muyo S, Stöcker W. Functional and structural insights into astacin metallopeptidases. Biol Chem. 2012;393(10):1027–1041.
   PubMed Web of Science ®Google Scholar
• Sterchi EE, Stöcker W, Bond JS. Meprins, membrane-bound and secreted astacin metalloproteinases. Mol Asp Med. 2008;29(5):309–328.
   PubMed Web of Science ®Google Scholar
• Scharfenberg F, Armbrust F, Marengo L, Pietrzik C, Becker-Pauly C. Regulation of the alternative β-secretase meprin β by ADAM-mediated shedding. Cell Mol Life Sci. 2019;76(16):3193–3206.
   PubMed Web of Science ®Google Scholar
• Peters F, Scharfenberg F, Colmorgen C, Armbrust F, Wichert R, Arnold P, Potempa B, Potempa J, Pietrzik CU, Häsler R, et al. Tethering soluble meprin α in an enzyme complex to the cell surface affects IBD-associated genes. FASEB J. 2019;33(6):7490–7504.
   PubMed Web of Science ®Google Scholar
• Broder C, Becker-Pauly C. The metalloproteases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. Biochem J. 2013;450(2):253–264.
   PubMedGoogle Scholar
• Prox J, Arnold P, Becker-Pauly C. Meprin α and meprin β: procollagen proteinases in health and disease. Matrix Biol. 2015;44-46:7–13.
   PubMed Web of Science ®Google Scholar
• Lottaz D, Maurer CA, Hahn D, Büchler MW, Sterchi EE. Nonpolarized secretion of human meprin alpha in colorectal cancer generates an increased proteolytic potential in the stroma. Cancer Res. 1999;59(5):1127–1133.
   PubMed Web of Science ®Google Scholar
• Lottaz D, Maurer CA, Noël A, Blacher S, Huguenin M, Nievergelt A, Niggli V, Kern A, Müller S, Seibold F, et al. Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancer. PLOS One. 2011;6(11):e26450.
   PubMed Web of Science ®Google Scholar
• Minder P, Bayha E, Becker-Pauly C, Sterchi EE. Meprinα transactivates the epidermal growth factor receptor (EGFR) via ligand shedding, thereby enhancing colorectal cancer cell proliferation and migration. J Biol Chem. 2012;287(42):35201–35211.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen J, Wang J, Yu F, Zhao S, Zhang Y, Tang H, Peng Z. Metalloproteases meprin-ɑ (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer. BMC Cancer. 2016;16(1):383.
   PubMedGoogle Scholar
• OuYang H-Y, Xu J, Luo J, Zou R-H, Chen K, Le Y, Zhang Y-F, Wei W, Guo R-P, Shi M. MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. Hepatology. 2016;63(4):1227–1239.
   PubMed Web of Science ®Google Scholar
• Breig O, Yates M, Neaud V, Couchy G, Grigoletto A, Lucchesi C, Prox J, Zucman-Rossi J, Becker-Pauly C, Rosenbaum J. Metalloproteinase meprin α regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein reptin. Oncotarget. 2017;8(5):7839–7851.
   PubMedGoogle Scholar
• Grainger AT, Pilar N, Li J, Chen M-H, Abramson AM, Becker-Pauly C, Shi W. Identification of Mep1a as a susceptibility gene for atherosclerosis in mice. Genetics. 2021;219(4):iyab160.
   PubMed Web of Science ®Google Scholar
• Ge W, Hou C, Zhang W, Guo X, Gao P, Song X, Gao R, Liu Y, Guo W, Li B, et al. Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation. J Mol Cell Cardiol. 2021;152:52–68.
   PubMed Web of Science ®Google Scholar
• Gao R, Liu D, Guo W, Ge W, Fan T, Li B, Gao P, Liu B, Zheng Y, Wang J. Mep1A enhances TNF-alpha secretion by mast cells and aggravates abdominal aortic aneurysms. Br J Pharmacol. 2020;177(12):2872–2885.
   PubMed Web of Science ®Google Scholar
• Schäffler H, Li W, Helm O, Krüger S, Böger C, Peters F, Röcken C, Sebens S, Lucius R, Becker-Pauly C, et al. The cancer-associated meprin β variant G32R provides an additional activation site and promotes cancer cell invasion. J Cell Sci. 2019;132(11):jcs220665.
   PubMed Web of Science ®Google Scholar
• Gellrich A, Scharfenberg F, Peters F, Sammel M, Helm O, Armbrust F, Schmidt F, Lokau J, Garbers C, Sebens S, et al. Characterization of the cancer-associated meprin βeta variants G45R and G89R. Front Mol Biosci. 2021;8:702341.
   PubMed Web of Science ®Google Scholar
• Bien J, Jefferson T, Causevic M, Jumpertz T, Munter L, Multhaup G, Weggen S, Becker-Pauly C, Pietrzik CU. The metalloprotease meprin generates amino terminal-truncated amyloid peptide species. J Biol Chem. 2012;287(40):33304–33313.
   PubMed Web of Science ®Google Scholar
• Schönherr C, Bien J, Isbert S, Wichert R, Prox J, Altmeppen H, Kumar S, Walter J, Lichtenthaler SF, Weggen S, et al. Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site. Mol Neurodegener. 2016;11(11):19.
   PubMedGoogle Scholar
• Becker-Pauly C, Pietrzik CU. The metalloprotease meprin β is an alternative β-secretase of APP. Front Mol Neurosci. 2016;9:159.
   PubMed Web of Science ®Google Scholar
• Armbrust F, Colmorgen C, Pietrzik CU, Becker-Pauly C. The Alzheimer’s disease associated bacterial protease RgpB from P. gingivalis activates the alternative β-secretase meprin β thereby increasing Aβ generation. bioRxiv. 2019:748814.
   Google Scholar
• Berner DK, Wessolowski L, Armbrust F, Schneppenheim J, Schlepckow K, Koudelka T, Scharfenberg F, Lucius R, Tholey A, Kleinberger G, et al. Meprin β cleaves TREM2 and controls its phagocytic activity on macrophages. FASEB J. 2020;34(5):6675–6687.
   PubMed Web of Science ®Google Scholar
• Broder C, Arnold P, Vadon-Le Goff S, Konerding MA, Bahr K, Muller S, Overall CM, Bond JS, Koudelka T, Tholey A, et al. Metalloproteases meprin and meprin are C- and N-procollagen proteinases important for collagen assembly and tensile strength. Proc Natl Acad Sci USA. 2013;110(35):14219–14224.
   PubMed Web of Science ®Google Scholar
• Biasin V, Marsh LM, Egemnazarov B, Wilhelm J, Ghanim B, Klepetko W, Wygrecka M, Olschewski H, Eferl R, Olschewski A, et al. Meprin β, a novel mediator of vascular remodelling underlying pulmonary hypertension. J Pathol. 2014;233(1):7–17.
   PubMed Web of Science ®Google Scholar
• Biasin V, Wygrecka M, Marsh LM, Becker-Pauly C, Brcic L, Ghanim B, Klepetko W, Olschewski A, Kwapiszewska G. Meprin β contributes to collagen deposition in lung fibrosis. Sci Rep. 2017;7:39969.
   PubMed Web of Science ®Google Scholar
• Kruse M-N, Becker C, Lottaz D, Köhler D, Yiallouros I, Krell H-W, Sterchi EE, Stöcker W. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J. 2004;378(Pt 2):383–389.
   PubMedGoogle Scholar
• Herzog C, Haun RS, Kaushal GP. Role of meprin metalloproteinases in cytokine processing and inflammation. Cytokine. 2019;114:18–25.
   PubMed Web of Science ®Google Scholar
• Herzog C, Seth R, Shah SV, Kaushal GP. Role of meprin A in renal tubular epithelial cell injury. Kidney Int. 2007;71(10):1009–1018.
   PubMed Web of Science ®Google Scholar
• Kaushal GP, Haun RS, Herzog C, Shah SV. Meprin A metalloproteinase and its role in acute kidney injury. Am J Physiol Renal Physiol. 2013;304(9):F1150–F1158.
   PubMed Web of Science ®Google Scholar
• Herzog C, Marisiddaiah R, Haun RS, Kaushal GP. Basement membrane protein nidogen-1 is a target of meprin β in cisplatin nephrotoxicity. Toxicol Lett. 2015;236(2):110–116.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Bond JS. Prointerleukin-18 is activated by meprin beta in vitro and in vivo in intestinal inflammation. J Biol Chem. 2008;283(46):31371–31377.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Jin G, Bradley SG, Matters GL, Gailey RD, Crisman JM, Bond JS. Balance of meprin A and B in mice affects the progression of experimental inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2011;300(2):G273–G282.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13(12):904–927.
   PubMed Web of Science ®Google Scholar
• Dufour A, Overall CM. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci. 2013;34(4):233–242.
   PubMed Web of Science ®Google Scholar
• Madoux F, Tredup C, Spicer TP, Scampavia L, Chase PS, Hodder PS, Fields GB, Becker-Pauly C, Minond D. Development of high throughput screening assays and pilot screen for inhibitors of metalloproteases meprin α and β. Biopolymers. 2014;102(5):396–406.
   PubMed Web of Science ®Google Scholar
• Ramsbeck D, Hamann A, Schlenzig D, Schilling S, Buchholz M. First insight into structure–activity relationships of selective meprin β inhibitors. Bioorg Med Chem Lett. 2017;27(11):2428–2431.
   PubMed Web of Science ®Google Scholar
• Ramsbeck D, Hamann A, Richter G, Schlenzig D, Geissler S, Nykiel V, Cynis H, Schilling S, Buchholz M. Structure-guided design, synthesis, and characterization of next-generation meprin β inhibitors. J Med Chem. 2018;61(10):4578–4592.
   PubMed Web of Science ®Google Scholar
• Tan K, Jäger C, Schlenzig D, Schilling S, Buchholz M, Ramsbeck D. Tertiary-amine-based inhibitors of the astacin protease meprin α. ChemMedChem. 2018;13(16):1619–1624.
   PubMed Web of Science ®Google Scholar
• Linnert M, Fritz C, Jäger C, Schlenzig D, Ramsbeck D, Kleinschmidt M, Wermann M, Demuth H-U, Parthier C, Schilling S. Structure and dynamics of meprin β in complex with a hydroxamate-based inhibitor. IJMS. 2021;22(11):5651.
   Google Scholar
• Becker-Pauly C, Barré O, Schilling O, Auf Dem Keller U, Ohler A, Broder C, Schütte A, Kappelhoff R, Stöcker W, Overall CM. Proteomic analyses reveal an acidic prime side specificity for the astacin metalloprotease family reflected by physiological substrates. Mol Cell Proteomics. 2011;10(9):M111.009233.
   PubMed Web of Science ®Google Scholar
• Villa JP, Bertenshaw GP, Bond JS. Critical amino acids in the active site of meprin metalloproteinases for substrate and peptide bond specificity. J Biol Chem. 2003;278(43):42545–42550.
   PubMed Web of Science ®Google Scholar
• Hou S, Diez J, Wang C, Becker-Pauly C, Fields GB, Bannister T, Spicer TP, Scampavia LD, Minond D. Discovery and optimization of selective inhibitors of meprin α (part I). Pharmaceuticals. 2021;14(3):203.
   Google Scholar
• Wang C, Diez J, Park H, Spicer TP, Scampavia LD, Becker-Pauly C, Fields GB, Minond D, Bannister TD. Discovery and optimization of selective inhibitors of meprin α (part II). Pharmaceuticals. 2021;14(3):197.
   Google Scholar
• Tan K, Jäger C, Körschgen H, Geissler S, Schlenzig D, Buchholz M, Stöcker W, Ramsbeck D. Heteroaromatic inhibitors of the astacin proteinases meprin α, meprin β and ovastacin discovered by a scaffold-hopping approach. ChemMedChem. 2021;16(6):976–988.
   PubMed Web of Science ®Google Scholar
• Heller ST, Natarajan SR. 1,3-diketones from acid chlorides and ketones: a rapid and general one-pot synthesis of pyrazoles. Org Lett. 2006;8(13):2675–2678.
   PubMed Web of Science ®Google Scholar
• Riley K, Tran K-A. Strength and character of R–X···π interactions involving aromatic amino acid sidechains in protein-ligand complexes derived from crystal structures in the protein data bank. Crystals. 2017;7(9):273.
   Web of Science ®Google Scholar
• Adiguzel E, Yilmaz F, Emirik M, Ozil M. Synthesis and characterization of two new hydroxamic acids derivatives and their metal complexes. An investigation on the keto/enol, E/Z and hydroxamate/hydroximate forms. J Mol Struct. 2017;1127:403–412.
   Web of Science ®Google Scholar
• Citarella A, Moi D, Pinzi L, Bonanni D, Rastelli G. Hydroxamic acid derivatives: from synthetic strategies to medicinal chemistry applications. ACS Omega. 2021;6(34):21843–21849.
   PubMed Web of Science ®Google Scholar
• Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. ‎J. Mol. Biol. 1997;267(3):727–748.
   PubMed Web of Science ®Google Scholar
• Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins. 2003;52(4):609–623.
   PubMed Web of Science ®Google Scholar
• Lovell SC, Word JM, Richardson JS, Richardson DC. The penultimate rotamer library. Proteins. 2000;40(3):389–408.
   PubMed Web of Science ®Google Scholar
• Molecular operating environment (MOE), 2019.01. Montreal: Chemical Computing Group ULC; 2019.
   Google Scholar
• Schlenzig D, Wermann M, Ramsbeck D, Moenke-Wedler T, Schilling S. Expression, purification and initial characterization of human meprin β from Pichia pastoris. Protein Expr Purif. 2015;116:75–81.
   PubMed Web of Science ®Google Scholar
• Bayly-Jones C, Lupton CJ, Fritz C, Venugopal H, Ramsbeck D, Wermann M, Jäger C, Marco A. d, Schilling S, Schlenzig D. Helical ultrastructure of the metalloprotease meprin α in complex with a small molecule inhibitor. Nat Commun. 2022;13(1):6178.
   PubMed Web of Science ®Google Scholar
• Morrison JF. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta. 1969;185(2):269–286.
   PubMedGoogle Scholar